Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar sustained vision gains in year two with quarterly injections compared to monthly ranibizumab Reductions in central retinal thickness were lower in [...]
The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen Approvals in the United States and Europe are anticipated in 2020 DUBLIN, IRELAND – [...]
Zurich-Schlieren, Switzerland, August 06, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) of its strategic partner Allergan for abicipar, a [...]
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB MultiSpecific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products ZURICH-SCHLIEREN, SWITZERLAND and THOUSAND OAKS, Calif.– (Dec. 19, 2018) – Molecular Partners AG (SIX: [...]
Zurich-Schlieren, May 30, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 [...]
Zurich-Schlieren, May 12, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., cofounder of the company, as Chief Executive Officer and to nominate him [...]
Long-term venture capital investors holding reduced to 28% of share capital. Private investors acquired shares from venture capitalist investors in secondary block trades. Zurich-Schlieren, April 6, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today reported changes [...]
Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions Symetis’ [...]
Tianjin, People’s Republic of China, 27 June 2016 – Quid, headquartered in San Francisco, was today awarded as one of the World Economic Forum’s Technology Pioneers, a selection of the world’s most innovative companies. Quid is software that searches, analyzes and visualizes the world’s collective intelligence to help answer [...]
Zurich‐Schlieren, July 07, 2015. Molecular Partners AG (ticker: MOLN) today announced that its partner Allergan has initiated phase III clinical trials with abicipar pegol (abicipar) for the treatment of wet age‐related macular degeneration (wet AMD). The event triggered a clinical milestone payment to Molecular Partners of USD 15 million. [...]